Innate Pharma (IPHA) Gains from Investment Securities (2023)
Innate Pharma (IPHA) reported Gains from Investment Securities of -$1.1 million for Q2 2023.
Innate Pharma (IPHA) Gains from Investment Securities (2023) Analysis & Trends
Innate Pharma has reported Gains from Investment Securities for 1 years, with the latest figure at -$1.1 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -1.14 Mn |
| Jun 30, 2023 | -1.14 Mn |